Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nerve; Lesion Clear all
Recruiting No phase listed Observational

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

NCT06222203
View directory record Official record
Conditions
Neurofibromatosis 1, Nerve Sheath Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 120 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Recruiting Phase 1Phase 2 Interventional

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

NCT04750928
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
Abemaciclib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Completed No phase listed Observational

Determination of Fraction Size Equivalent Dose (FED) Levels for Intracranial Conformal Avoidance Radiotherapy

NCT00214175
View directory record Official record
Conditions
Glioma, Brain Neoplasms
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Sep 11, 2026, 10:25 PM EDT
Recruiting Phase 2 Interventional

UCSD Image-Guided Cognitive-Sparing Radiosurgery for Intracranial Lesions

NCT04343157
View directory record Official record
Conditions
Brain Metastases, Adult, Neurocognitive Function, Cancer, Meningioma of Brain, Arteriovenous Malformations, Cerebral
Interventions
Cognitive Sparing Brain Stereotactic Radiosurgery (SRS)
Radiation
Lead sponsor
Jona Hattangadi-Gluth
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Completed No phase listed Observational

Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders

NCT00255671
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity
Interventions
Questionnaire
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 11, 2026, 10:25 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690
View directory record Official record
Conditions
Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Interventions
Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser, Sham Microinjector
Drug · Device
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 1 Interventional

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

NCT01017185
View directory record Official record
Conditions
Refractory Head and Neck Cancer, Squamous Cell Carcinoma, Skin, Carcinoma of the Breast, Malignant Melanoma
Interventions
HF10
Drug
Lead sponsor
Takara Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
The Bronx, New York • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 11, 2026, 10:25 PM EDT
Completed No phase listed Observational

Prospective Study of 2 mm Margins for the Biopsy of Dysplastic Nevi

NCT03094273
View directory record Official record
Conditions
Dysplastic Nevi
Interventions
Saucerization biopsy
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 11, 2026, 10:25 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

NCT07493447
View directory record Official record
Conditions
Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions
Panitumumab-IRDye800
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated No phase listed Observational

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

NCT05266430
View directory record Official record
Conditions
Choroidal Melanoma, Indeterminate Lesions
Interventions
Standard of Care, AU-011
Other · Drug
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Royal Oak, Michigan • Portland, Oregon • Greenville, South Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

NCT00879658
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

NCT00348790
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Sarcoma
Interventions
vatalanib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 11, 2026, 10:25 PM EDT
Enrolling by invitation No phase listed Observational

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

NCT07338968
View directory record Official record
Conditions
Choroidal Melanoma, Indeterminate Lesions
Interventions
Observational
Other
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
10
States / cities
Sacramento, California • Ann Arbor, Michigan • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Not applicable Interventional

Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for Melanoma

NCT01191294
View directory record Official record
Conditions
Skin Simulation Model, Mastery Learning Model to Simulation Training for Visual Screening for Melanoma and Skin Biopsy
Interventions
Simulation teaching session
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Pigmented Skin Lesions With MelaFind(R) System

NCT00434057
View directory record Official record
Conditions
Melanoma
Interventions
MelaFind(R)
Device
Lead sponsor
MELA Sciences, Inc.
Industry
Eligibility
Not listed
Enrollment
1,383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Plantation, Florida • Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 11, 2026, 10:25 PM EDT
Completed No phase listed Observational

Cost Effectiveness of OMT for Chronic Low Back Pain

NCT03532230
View directory record Official record
Conditions
Lumbar Radiculopathy, Lesion of Sciatic Nerve, Left Lower Limb, Lesion of Sciatic Nerve, Right Lower Limb, Lumbar Spinal Stenosis, Lumbar Spondylosis, Lumbago With Sciatica, Left Side, Lumbago With Sciatica, Right Side
Interventions
Osteopathic Manipulative Treatment (OMT)
Procedure
Lead sponsor
Rowan University
Other
Eligibility
18 Years to 84 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
East Lansing, Michigan • Stratford, New Jersey • Voorhees Township, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 1Phase 2 Interventional

In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation

NCT00861107
View directory record Official record
Conditions
Metastatic Cancer
Interventions
AlloStim-7, percutaneous tumor cryoablation, AlloStim8 or AlloStim-9
Biological · Procedure
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 11, 2026, 10:25 PM EDT
Completed No phase listed Observational

DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin Cancer

NCT06690086
View directory record Official record
Conditions
Skin Cancer
Interventions
Lesion biopsy, DermaSensor Device Use
Procedure · Device
Lead sponsor
DermaSensor, Inc.
Industry
Eligibility
22 Years and older
Enrollment
1,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions

NCT00091689
View directory record Official record
Conditions
Melanoma
Interventions
852A
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Lebanon, New Hampshire • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 26, 2008 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Post-Approval Study of MelaFind

NCT01700114
View directory record Official record
Conditions
Melanoma
Interventions
MelaFind
Device
Lead sponsor
MELA Sciences, Inc.
Industry
Eligibility
Not listed
Enrollment
487 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
6
States / cities
Englewood, Colorado • Tallahassee, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 11, 2026, 10:25 PM EDT
Recruiting Not applicable Interventional

MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas

NCT04373720
View directory record Official record
Conditions
Glioma
Interventions
Magnetic Resonance Elastography, Magnetic Resonance Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Not applicable Interventional Results available

Cooled Radiofrequency vs. Hyaluronic Acid to Manage Knee Pain

NCT03381248
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Cooled Radiofrequency, Hyaluronic Acid Injection, Crossover from Hyaluronic Acid Injection to Cooled Radiofrequency
Device · Other
Lead sponsor
Avanos Medical
Other
Eligibility
21 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Coeur d'Alene, Idaho • New Orleans, Louisiana • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Not applicable Interventional Results available

Nerve Stimulator for Patients With Upper Extremity Disease, Vascular or Orthopedic Surgery

NCT03112642
View directory record Official record
Conditions
Other Biomechanical Lesions of Upper Extremity
Interventions
Local anesthetic block [0.35% marcaine], Braun DIG-R-C Stimuplex Blockade Monitor System
Procedure · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years to 89 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 2 Interventional

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

NCT06322342
View directory record Official record
Conditions
Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Brain Cancer, Brain Tumor, Brain Neoplasm, Primary, Multiple Sclerosis, Multiple Sclerosis Brain Lesion, Neurofibroma, Acoustic Neuroma, CNS Tumor, CNS Lesion, CNS Metastases, CNS Cancer, CNS Lymphoma, Von Hippel Lindau, Meningioma, Glioma, Schwannomas, Neuroinflammation, Neoplasia
Interventions
RVP-001
Drug
Lead sponsor
Reveal Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
New Haven, Connecticut • Boston, Massachusetts • Columbia, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 11, 2026, 10:25 PM EDT